MIBI BlogResearchers at Bristol Myers Squibb (BMS) are leading the charge in advancing the understanding of diffuse large B-cell lymphoma (DLBCL), leveraging cutting-edge technology to uncover critical insights. Using high-resolution imaging, the BMS research team is...

MIBI BlogNSCLC PatientRecent advancements in cancer treatment emphasize the importance of understanding the tumor microenvironment (TME) and its immune responses. A groundbreaking Phase 1 clinical trial using Ionpath’s Multiplexed Ion Beam Imaging (MIBI™) technology...

MIBI BlogIn the rapidly evolving world of spatial biology, it can be challenging for scientists to keep up with the latest platforms and applications. That’s why a new textbook is cause for celebration: it establishes the current spatial proteomics landscape and walks...

MIBI BlogHere at Ionpath, we’re lucky to have an incredible team of people who make our company and our multiplex ion beam imaging (MIBI) technology possible. In this new blog series, we’ll introduce you to some of our team members. First up is Sean Pawlowski,...

MIBI BlogMultiplexed Ion Beam Imaging (MIBI)’s groundbreaking advancements were proudly showcased at the American Society for Mass Spectrometry (ASMS) 2024 in three different posters and an oral presentation. These studies emphasize the power of MIBI in enhancing the...

MIBI BlogThe field of immuno-oncology relies on understanding the interplay between tumor cells and the immune system within the tumor microenvironment (TME). Traditional methods like immunohistochemistry (IHC) and immunofluorescence (IF) have limitations. Here, we...

MIBI BlogA new paper from scientists at Stanford University and The Gladstone Institutes offers a look at how spatial proteomic technology can unravel the mysteries of neurodegenerative disorders such as Alzheimer’s disease. The preprint, recently posted to bioRxiv,...

MIBI BlogA new molecular map of small cell lung cancer (SCLC) is shedding light on how the aggressive malignancy spreads so quickly and why it’s so difficult to treat. Employing single-cell transcriptome sequencing and multiplexed ion beam imaging (MIBI™)...

MIBI BlogEvery year, the Ionpath team looks forward to one of the leading conferences for immuno-oncology research: the annual meeting of the Society for Immunotherapy of Cancer, better known as SITC. For this year’s event, we were honored to present a poster, and to...

MIBI BlogNew approach provides spatial multi-omic analysis of an HIV modelIn a new preprint posted to bioRxiv, scientists at Stanford University, Oregon Health & Science University, and the Dana-Farber Cancer Institute report findings from the multi-omic analysis...

MIBI BlogResearch team aimed to identify and map immune players in tuberculosis granulomasResearchers have long known that the immune response to the Mycobacterium tuberculosis pathogen leads to the formation of granulomas, or clusters of immune cells designed to...

MIBI BlogTo understand signs of progression to invasive breast cancerIt’s a decades-old mystery among oncologists: why do some women diagnosed with non-invasive breast tumors progress to invasive breast cancer while others do not? Understanding this — and being able...